



# 2017 Retinal Pharmaceuticals and Biologics Report

A Global Market Analysis for 2016 to 2022

88

CHARTS AND TABLES

261

COMPREHENSIVE  
PAGES

27

COMPANY PROFILES

8

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

**AUTHOR**  
Peter Downs

**RELEASED**  
October 2017

The 2017 Retinal Pharmaceuticals and Biologics Report has significant enhancements from previous reports, with updated estimates of the prevalence of diabetes and new extended analysis and discussions of diseases.

## Market Scope

# 2017 Retinal Pharmaceuticals and Biologics Report

Market Scope's 2017 Retina Pharmaceuticals and Biologics Report provides in-depth coverage of current and future pharmaceuticals and biologics used in treating retinal diseases.

### Eight Categories Are Analyzed In This Report:


VEGF Inhibitors, PDGF Inhibitors, Neuroprotectors, Complement Cascade Inhibitors, Visual Cycle Modulators, Gene Therapies, Corticosteroids, and Other Mechanisms of Action

### Each Market Segment Includes:

An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

### Also Included in This Report:

- Review of Retinal Diseases and Treatments
- Symptoms, Diagnosis, and Treatment of AMD
- Diagnosis and Management of Diabetic Retinopathy and Macular Edema
- An Overview of Other Retinal Diseases and Conditions
- Epidemiology of Retinal Disease
- Patient Economics and Reimbursement
- Retina Specialists and Training
- Current Retinal Pharmaceuticals in the Marketplace
- 27 Company Profiles
- 41 Color Tables and 47 Color Figures



Our report on the retinal pharmaceuticals and biologics market is in its eighth edition. It is a leading industry source for accurate and relevant information on all aspects of the market. We cover prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We discuss the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and analyze treatment patterns and trends. We also forecast product demand in units and dollars, and we analyze market shares by product category.

> This report includes market data for 2016, and we forecast market performance through 2022.

## How to Order

Order your 2017 Retinal Pharmaceuticals and Biologics Market Report now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2017 Retinal Pharmaceuticals  
and Biologics Report

**\$10,200**

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*



### SINGLE-USER LICENSE

2017 Retinal Pharmaceuticals  
and Biologics Report

**\$6,800**

- + Additional Printable Electronic PDF **\$500**
- + Additional Paper Copy **\$300**



### ADD-ONS

- + Disease Model by Country
- + Custom Market Analysis

**\$ CALL FOR PRICING**

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

*Please add \$50 for shipping if ordering from outside the US.*

## Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

- Our proprietary global disease population and demographic models
- Twenty years and counting of ophthalmologist survey data
- Analysis of company published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in major, worldwide ophthalmic meetings
- Interviews and long-standing relationships with company executives and ophthalmologists



# About Us

Market Scope is recognized as the leading source for accurate and timely industry information in ophthalmology.

We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return-on-investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.

## TABLE OF CONTENTS

### INTRODUCTION

- Scope
- Methodology
- About the Author
- The Report at a Glance

### EXECUTIVE SUMMARY

- Transformative Years
- Market Drivers
- The Retinal Pharmaceutical Products Market
- Leading Competitors' Revenues
- Leading Competitors' Units
- Market Trends

### THE RETINA

#### INTRODUCTION TO RETINAL DISEASES

- Treatment Modalities
- Therapeutic Targets
- Global Retinal Disease Forecast

#### AGE-RELATED MACULAR DEGENERATION

- Dry AMD
  - Geographic Atrophy (GA)
  - Wet (Neovascular) AMD
- Polypoidal Choroidal Vasculopathy (PCV)
- Retinal Angiomatous Proliferation
- Simultaneous Neovascular AMD and GA
- AMD Risk Factors
- Symptoms of AMD
- Diagnosis and Management
- Diagnostic Technologies
- Therapies
  - Pharmaceutical Therapy
  - Biologic Therapy
  - Laser Therapy
- Estimates for Age-Related Macular Degeneration
- Age-Related Macular Degeneration by Category

#### DIABETIC EYE DISEASE

- Diabetes
- Diabetic Retinopathy
  - Nonproliferative Diabetic Retinopathy
  - Proliferative Diabetic Retinopathy (PDR)
- Diabetic Macular Edema (DME)
- DR and DME Risk Factors
- Blood Glucose, Blood Pressure and Blood Lipids
- Race and Ethnicity
- Glitazones and DME
- Diagnosis and Management
- Pharmaceutical Therapy
- Biologics Therapy
- Laser Therapy
- Cryotherapy
- Vitreotomy
- Estimates for Diabetic Eye Diseases (DR and DME)
- Diabetic Eye Disease by Category

#### RETINAL VEIN OCCLUSION

- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
- Risk Factors
- Diseases and Conditions
- Gender
- Lifestyle Factors
- Diagnosis and Management
- Pharmaceutical Therapy
- Biologics Therapy
- Laser Therapy
- Estimates for Retinal Vein Occlusion
- Retinal Vein Occlusion by Category

#### ADHESIONS, HOLES, TEARS, AND DETACHMENTS

- Symptomatic Vitreomacular Adhesion (VMA)
- Retinal Tears, Holes, and Detachments
- Retinal Detachment
- Estimates for Retinal Holes, Tears, and Detachments

### INHERITED RETINOPATHIES

- Achromatopsia
- Other Heritable Color Vision Deficiency
- Choroideremia
- Leber Congenital Amaurosis
- Leber Hereditary Optic Neuropathy
- Stargardt Macular Degeneration
- Usher Syndrome
- X-linked Juvenile Retinoschisis
- Retinitis Pigmentosa
- Additional Inherited Retinal Dystrophies
- Estimates for Inherited Retinopathies

### NONINFECTIOUS POSTERIOR UVEITIS

- Estimates for Noninfectious Posterior Uveitis
- Treatment

### MYOPIC CHOROIDAL NEOVASCULARIZATION

- Estimates for Myopic Choroidal Neovascularization
- Treatment

### ADDITIONAL RETINAL DISEASES

- Central Serous Chorioretinopathy (CSCR)
- CMV Retinitis
- Epiletinal Membrane (ERM)
- Infectious Chorioretinitis
- Retinal Artery Occlusion
- Retinoblastoma
- Retinopathy of Prematurity (ROP)
- Estimates for Other Retinal Diseases

### PATIENT ECONOMICS AND REIMBURSEMENT

- Treatment, Access, and Cost
- Cost Controls
- Competition

### RETINA SPECIALISTS

- Retinal Training
- The Retina Subspecialty Worldwide
- Vitreoretinal Services
- Diagnosing and Monitoring
- Treatment
- Location of Retinal Services
- Conferences and Associations
- Retina Meetings
- Retina Societies

### RETINAL PHARMACEUTICALS IN THE MARKET

- Treatment before Anti-VEGFs
- Biologics
- History
- Biosimilars Defined
- Lucentis from Genentech (Roche) and Novartis
- Avastin from Genentech (Roche)
- Comparisons of Lucentis and Avastin
- Sales of Lucentis and Avastin
- Macugen from Valeant Pharmaceuticals/Pfizer
- Eylea from Regeneron/Bayer Healthcare
- Conbercept from Chengdu Kanghong Biotech
- Anti-VEGF Regimens
- ThromboGenics' Jetrera
- AbbVie's Humira
- Acthar from Mallinckrodt
- On the Horizon
- Pharmaceuticals
- Visudyne (Photodynamic Therapy) from Valeant
- Pharmaceuticals/Novartis
- Ophthalmic Corticosteroids
- Raxone from Santhera Pharmaceuticals
- On the Horizon
- Summary Table of Treatments for Retinal Disease
- Other Marketed Pharmaceuticals with Retinal Applications

### RETINAL PHARMACEUTICALS IN DEVELOPMENT

- VEGF Inhibition
  - Novartis: Brodalizumab (RTH258)
  - Allergan: Abicipar pegol (AGN-150998)
  - Ohr Pharmaceuticals: Squalamine (OHR-102) used in conjunction with Lucentis
- Other New Anti-VEGFs in Development
- PDGF and VEGF Inhibition
- Other Vascular Growth Factor Inhibitors
- Kinase Inhibition
- RNA Interference
- Ang-2 Inhibition
- Tie2 Activation
- Endoglin Inhibition
- Tissue Factor Inhibition
- Targeting the Complement Cascade
- Genentech (Roche): Lampalizumab (Anti-Factor D)
- Ophthotech: Zimura (ARC1905)
- Other Complement Factor Inhibitors in Development
- Antisense Technology
- Gene Signal: Aganirsen
- Neuroprotection
- Allergan: Brimonidine IVT Implant
- Other Neuroprotectors in Development
- Mitochondrial Protection
- Modulating the Visual Cycle
- Novelion Therapeutics: Zuretinol Acetate
- Other Visual Cycle Modulators
- Plasma Kallikrein Inhibitors
- Amyloid Antibodies
- Gene Therapies
- Spark Therapeutics: Luxturna (voretigene neparvovec)
- GenSight: GS010 (rAAV2-ND4)
- Huazhong University of Science and Technology: rAAV2-ND4
- Optogenetics
- Other Gene Therapy Studies
- Stem Cell Therapies
- Anti-inflammatories
- Corticosteroids
- Cytokine Signaling Inhibitors
- Other Mechanisms of Action
- MacuCLEAR: MC-1101
- Recap of Programs in Phase III Development

### INVESTIGATIONAL SUSTAINED-DELIVERY DEVICES

- Allergan: Brimonidine IVT Implant
- Roche: Ranibizumab Port Delivery System

### GLOBAL MARKET FORECASTS

- Market Snapshot and Drivers
- Factors Depressing Market Revenues
- Factors Increasing Market Revenues
- Key Forecast Components
- Market for Retinal Pharmaceuticals and Biologics
- The Global Market
- Global Retinal Disease Market Forecast
- Treatment Rate
- New Products Will Increase Diversity of Choices, Return Growth to Total Market Revenues
- Market Overview by Region
- The US: A Mature Market Awaits New Products
- W. Europe: First to Treat Inherited Retinal Disease
- Japan: Slow Growth
- Other Wealthy Nations: Uneven Prospects
- China: Extending Access
- India: Low-Cost Pioneer
- Latin America: Going to Extremes
- Rest of World (ROW): Above Average Growth
- Notes on Forecasts
- Therapeutics for Geographic Atrophy
- Therapeutics for Inherited Retinopathies

### NUTRACEUTICALS

#### AREDS FINDINGS

- AREDS
- AREDS2
- OCULAR DYES
  - Trypan Blue
  - Infracyanine Green
  - Infracyanine Green
  - Brilliant Blue Green
  - Natural Dyes
  - Supplier

#### NEW NONPHARMACOLOGICAL THERAPIES

- Laser Therapy
- Ellex' Retinal Regeneration Therapy (2RT)
- Targeted Laser Photocoagulation from OD-OS
- Radiation Therapies
- IRay Stereotactic Radiotherapy
- Hand-held Brachytherapy Device from Salutaris
- Medical Devices
- Electrical Neurostimulation for Slowing RP's Vision Loss
- Low-Energy Electrical Stimulation - Okuvision GmbH
- Implants for Regaining Lost Vision
- Retinal Prosthesis Projects
- Implantable Miniature Telescope from VisionCare

#### COMPANY PROFILES

- AbbVie Inc.
- Alcon, Inc.
- Alimera Sciences
- Allegro Ophthalmics
- Allergan, Plc.
- Apellis Pharmaceuticals
- Bayer HealthCare AG
- Chengdu Kanghong Biotechnology Co., Ltd.
- Clearside Biomedical, Inc.
- Formycon AG
- Gene Signal
- Genentech
- GenSight Biologics
- Intas Pharmaceuticals Ltd
- Mallinckrodt Pharmaceuticals
- Molecular Partners AG
- Novartis International AG
- Ophthotech Corporation
- Ohr Pharmaceuticals
- PFEnex
- pSivida Limited
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Santhera Pharmaceutical Co., Ltd.
- Santhera Therapeutics
- Spark Therapeutics
- ThromboGenics NV
- Valeant Pharmaceuticals International

*Market Scope*

9859 Big Bend Blvd. Suite 202  
St. Louis, MO 63122  
[market-scope.com](http://market-scope.com)